Yu Yong
SEC CIK 1937482 · EDGAR
BoughtSold
Companies
| Ticker | Company | Title | Holding | Bought | Sold | Trades | First | Last |
|---|---|---|---|---|---|---|---|---|
| GNLX | GENELUX Corp | VP, Clinical Trial Ops | 258.7K | — | $3.27M | 31 | 2023-02-17 | 2026-08-31 |
Most active insiders at GNLX, 12 months
| # | Insider | Title | Bought | Sold |
|---|---|---|---|---|
| 1 | Zindrick Thomas | Pres, CEO | — | $117.7K |
| 2 | Thomas John | Dir | — | $108.8K |
| 3 | Smither John W | Dir | — | $34.9K |
| 4 | Cappello Joseph | Chief Technical Off | — | $34.0K |
| 5 | Yu Yong | SVP, Clinical Development | — | $32.6K |
| 6 | Smalling Ralph | Head of Regulatory | — | $2,804 |
| 7 | Pulisic Matthew | CFO | — | — |
| 8 | Mirabelli Mary | Dir | — | — |
| 9 | Groen Eric | GC | — | — |
| 10 | Tyree James L | Dir | — | — |
Transactions 31
| X | Filed | Traded | Ticker | Company | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-09-02 19:05 | 2026-08-31 | GNLX | GENELUX Corp | Yu Yong | CSO | S - Sale | $2.75 | -9,683 | 258.7K | -4% | -$26.7K | |
| 2026-08-04 20:20 | 2026-08-04 | GNLX | GENELUX Corp | Yu Yong | CSO | S - Sale | $2.94 | -653 | 268.4K | -0.2% | -$1,922 | |
| 2026-06-18 19:05 | 2026-06-16 | GNLX | GENELUX Corp | Yu Yong | CSO | A - Grant | $0.00 | +119.3K | 269.0K | +80% | $0 | |
| 2026-05-12 20:30 | 2026-05-11 | GNLX | GENELUX Corp | Yu Yong | CSO | S - Sale | $2.97 | -605 | 149.7K | -0.4% | -$1,798 | |
| 2026-03-26 | 2026-03-24 | GNLX | GENELUX Corp | Yu Yong | SVP, Clinical Development | S - Sale | $2.42 | -906 | 144.9K | -0.6% | -$2,193 | |
| M | 2025-12-11 | 2025-08-21+ | GNLX | GENELUX Corp | Yu Yong | SVP, Clinical Development | S - Sale | $3.83 | -4,192 | 145.8K | -3% | -$16.0K |
| D | 2025-08-29 | 2025-08-27 | GNLX | GENELUX Corp | Yu Yong | SVP, Clinical Development | A - Grant | $0.00 | +101.5K | 150.0K | +209% | $0 |
| 2025-05-13 | 2025-05-12 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $2.92 | -5,579 | 47.6K | -10% | -$16.3K | |
| 2025-04-17 | 2025-03-14 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +13.3K | 53.2K | +33% | $0 | |
| D | 2024-12-20 | 2024-12-18 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +29.0K | 39.9K | +267% | $0 |
| 2024-07-08 | 2024-06-24 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $2.12 | -6,849 | 10.9K | -39% | -$14.5K | |
| M | 2024-07-08 | 2024-02-19+ | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | A - Grant | $0.00 | +15.2K | 17.7K | +609% | $0 |
| D | 2024-06-07 | 2024-05-29 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | P - Purchase | — | +2,500 | 2,500 | New | — |
| M | 2023-12-18 | 2023-12-15 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $13.16 | -32.5K | 5,803 | -85% | -$428.2K |
| 2023-12-08 | 2023-12-07 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $11.85 | -36.8K | 32.5K | -53% | -$436.1K | |
| 2023-11-22 | 2023-11-21 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $10.26 | -18.7K | 69.3K | -21% | -$191.5K | |
| M | 2023-11-21 | 2023-11-17+ | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $11.61 | -18.1K | 102.6K | -15% | -$210.5K |
| D | 2023-10-25 | 2023-10-24 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $19.11 | -5,200 | 106.1K | -5% | -$99.4K |
| D | 2023-10-25 | 2023-10-24 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| D | 2023-10-11 | 2023-10-10 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| DM | 2023-10-11 | 2023-10-10 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $22.01 | -5,200 | 106.5K | -5% | -$114.5K |
| DM | 2023-09-27 | 2023-09-26 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $23.56 | -5,200 | 109.5K | -5% | -$122.5K |
| D | 2023-09-27 | 2023-09-26 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +5,200 | 111.3K | +5% | +$31.2K |
| D | 2023-09-21 | 2023-09-20 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +6,000 | 112.1K | +6% | +$36.0K |
| D | 2023-09-21 | 2023-09-20 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $27.96 | -6,000 | 106.1K | -5% | -$167.8K |
| D | 2023-09-18 | 2023-09-15 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | M - OptEx | $6.00 | +10.4K | 116.5K | +10% | +$62.4K |
| DM | 2023-09-18 | 2023-09-15 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale+OE | $21.89 | -10.4K | 110.8K | -9% | -$227.6K |
| 2023-09-15 | 2023-09-13 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $21.14 | -29.8K | 106.1K | -22% | -$630.0K | |
| 2023-08-30 | 2023-08-30 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $24.70 | -19.8K | 135.9K | -13% | -$489.1K | |
| 2023-08-22 | 2023-08-18 | GNLX | GENELUX Corp | Yu Yong | VP, Clinical Trial Ops | S - Sale | $23.73 | -3,265 | 155.7K | -2% | -$77.5K | |
| 2023-05-02 | 2023-02-17 | GNLX | GENELUX Corp | Yu Tony | VP, Clinical Trial Ops | A - Grant | $0.00 | +9,000 | 159.0K | +6% | $0 |
Purchase Sale Sale after option exercise All abbreviations